JonesTrading analyst Matthew Cross maintained a Hold rating on Abeona Therapeutics (ABEO) yesterday. The company’s shares closed last Monday at $2.43, close to its 52-week low of $2.12.
According to TipRanks.com, Cross ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.8% and a 33.3% success rate. Cross covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Actinium Pharmaceuticals, and Aldeyra Therapeutics.
Abeona Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $11.83, a 386.8% upside from current levels. In a report issued on August 12, Cantor Fitzgerald also downgraded the stock to Hold with a $2 price target.
See today’s analyst top recommended stocks >>
Based on Abeona Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.92 million. In comparison, last year the company had a GAAP net loss of $11.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
